Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma

Sang-Eun YOON; Yeon-Jeong KIM; Joon-Ho SHIM; Donghyun PARK; Junhun CHO; Young-Hyeh KO; Woong-Yang PARK; Yeung-Chul MUN; Kyoung-Eun LEE; Duck CHO; Won-Seog KIM; Seok-Jin KIM.
Cancer Research and Treatment ; : 597-612, 2022.
Artículo en Inglés | WPRIM | ID: wpr-925679

Documentos relacionados

  1. Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma.
  2. Rapid detection of the MYD88 L265P mutation for pre- and intra-operative diagnosis of primary central nervous system lymphoma.
  3. Circulating Tumor DNA Reflects Histologic and Clinical Characteristics of Various Lymphoma Subtypes.
  4. EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.
  5. <i>Casitas B-lineage lymphoma</i> Gene Mutation Ocular Phenotype.
  6. Characterization of genomic alterations in primary central nervous system lymphomas.
  7. Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas.
  8. Real-life targeted next-generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network.
  9. Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma.
  10. CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.